Experimental cell treatment shows promise for COVID-19 lung failure
NCT ID NCT04447833
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a single dose of mesenchymal stromal cells in 7 COVID-19 patients with severe acute respiratory distress syndrome (ARDS) who were on ventilators. The main goal was to check safety, looking for serious side effects like heart problems or blood clots within 10 days. The study also tracked survival and changes in blood cells over time.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ARDS, HUMAN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Uppsala University Hospital
Uppsala, 75185, Sweden
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- What happens to the immune system after COVID-19? a major study aims to find out.
- Hidden toll of routine ICU procedure revealed: suctioning may spike pain and stress
- Why COVID-19 lungs fail: tiny blood vessel damage may be key
- Scientists probe why lung disease raises COVID-19 risk
- COVID-19's skin secrets: could chilblains hold clues to the virus?
- Scientists create COVID-19 biobank to unlock disease secrets